IL18 and neoplasm: In fact, the release of the main effectors of pyroptosis (IL‐1β, IL‐18 and HMGB1) breaks down the ‘cold’ tumour properties and increases the infiltration of anti‐tumour immune cells in the TME, while at the same time decreasing the infiltration of suppressor immune cells.122